#ELCC24
Meta-analysis of the efficacy of periop or neoadj ICI+ChT in NSCLC

7 RCTs, 2934 pts

pCR
All trial➡️22.7% vs 3.7%

EFS
Periop➡️HR:0.57
Neoadj➡️HR:0.66

📌After the analysis, the RATIONAL-315 trial also shared its first results. The general situation did not change when…

Excited to discuss abstracts 6MO and 244MO today at #ELCC24 . Come join us in the Forum Hall at 5pm.

Some of money 💰 slides from #ELCC24 ESMO - Eur. Oncology
Useful for quick references.
1 - Mandatory, emerging and exploratory predictive biomarkers in NSCLC
2- PFS and OS of all immunotherapy in advanced NSCLC in first line and second line
3- intracranial efficacy for all targated…

PACIFIC2 ⛔️: Durva+CTRT➡️Durva did not improve PFS/OS vs CTRT alone in sIII NSCLC
Patients were randomized upfront
Should we continue to explore this approach(CM73L)? OR test induction CT+IO➡️IO+CTRT with or w/o IO consolidation would be an optimal future approach?(KN799) #ELCC24

#ELCC
ADCs: the promising new therapy?

Discussing all things antibody-drug conjugates, join me, #EgbertSmit #IgnatioWistuba & ⁦Solange Peters⁩ in Forum Hall today at 10am

#ESMOambassadors #ELCC 24 ⁦ESMO - Eur. Oncology⁩ ⁦⁦Beaumont RCSI Cancer Centre⁩ ⁦RCSI⁩⁩

#ELCC24 : immunotherapy is a game winner in aNSCLC. Hwv, questions unresolved, benefit new drugs like anti-TIGIT (ph3 ⛔️in 1st L in PDL1⬆️ atezo plus tiragolumab no significant OS benefit…) anti LAG3, anti TIM3, dual ICB
Download very good presentation by Dr Reck@MartinReck2

On my way back home from #ELCC24 reflecting there is one thing that #AI will never manage to substitute: Human bonds, friendships that last , interactive thinking and this collective feeling of launching new scientific endeavours
🧬🧪🥼🔬 Safe journeys back home et à la…

Novel ADC targets and combination approaches. Terrific presentation by Solange Peters 🙌🏻👏🏻 ESMO - Eur. Oncology

#ELCC24 #ADC #nsclc #sclc #lcsm

All neo adjuvant and peroperative IO trials in NSCLC. Along with Rationale 315 ( tislelizumab plus neo adjuvant chemo )

Money 💰 slide by Jonathan Spicer MD PhD ESMO - Eur. Oncology #ELCC24

Debate about resection vs radiation for stage III NSCLC is going to start every second at #ELCC24
With Corinne Faivre-Finn 💙 and Jonathan Spicer

Oncólogos de 🇪🇸 y🇲🇽 nos han dados sus destacados en #ASCOGI24 #ascogu24 #ESMOSarcomaAndRareCancers24 #ELCC24 y #APCCC24 . Conéctate a oncobites.tv y mantente alerta porque seguiremos recorriendo el 🗺️ para mantenerte actualizado sobre eventos en oncología 🦀

The results of PACIFIC-2 presented at #ELCC24 helped us learn how patients tolerate the concurrent infusion of a PD-L1 checkpoint inhibitor with a platinum doublet while receiving ~30 daily fractions of thoracic radiotherapy. #radonc

#ELCC24 Young thoracic oncologists attention! Join the #ESMOYOC Clincial Cases Discussion at 17:00 in Club A for Advanced rare mutations, Primary resistance to immunotherapy, Brain mets and more Umberto Malapelle Ilit Turgeman Noemi Reguart Elene Mariamidze Myrto K. Moutafi ESMO - Eur. Oncology IASLC

✍️ The hand that writes the o̶p̶i̶o̶i̶d̶ amivantamab should also write the b̶o̶w̶e̶l̶r̶e̶g̶i̶m̶e̶n̶ dermatology consult

▪️Ppx tetracycline
▪️Moisturizer & topical steroids
▪️Tx interruption (grade 2+)
▪️Dermatology consult

#ELCC24 #lcsm

#ELCC24 We presented our multicentric cohort, showing that rechallenge is still a good option in ES SCLC in the chemoimmunotherapy era. Notably, outcomes were similar regardless of the platinum free interval (3-6 vs ≥ 6 months).Raffaele Califano ESMO - Eur. Oncology IASLC

Sucessful Clinical Case Discussion to finish all #ESMOYOC sessions in #ELCC24 with Drs. Alessandro Scala, Ilit Turgeman, David McMahon, Antonin Levy, Noemi Reguart Umberto Malapelle Hongcheng Zhu 祝鸿程 Elene Mariamidze Myrto K. Moutafi #ESMOAmbassadors ESMO - Eur. Oncology IASLC

Thrilled to share that my work on KRAS-driven lung adenocarcinoma organoids was honored with the Best Poster Award at the European Lung Cancer Congress (ELCC 2024) in Prague. It was a profound honor to receive this award from Pieter Hiemstra
#ELCC24 #Organoids
ESMO - Eur. Oncology IASLC

Academia has the power💪🏻.We need to test how to use the drugs.There’s a room to assess de-escalation immuno for patients (to ⬇️tox) and society (to ⬇️ econom tox) such PULSE trial (lead Benjamin Besse) testing ⬆️ interval btw pembro infusions (Q6W) keeping 200mg not 400 #ELCC24

📢 See you tomorrow 12.00-12.45 PM at poster display section to discuss our poster 'Germline testing in NSCLC: Real-world impact of the discovery of Pathogenic Germline Variants in the INHERITY LC study'
#ELCC24 ICAPEM ESMO - Eur. Oncology

Smart trial presented by Sun Min Lim #ELCC24 to specifically address the drug tolerant state. Window of opportunity trial testing osimertinib prior to surgery with pre/post treatment WES, RNAseq, scRNAseq. Hope it will help to decipher the DTP state in oncogene-addicted NSCLC.